Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Immunol Lett ; 239: 77-87, 2021 11.
Article in English | MEDLINE | ID: mdl-34508790

ABSTRACT

Cancer immunotherapy is emerging as a viable treatment option for several types of cancer. Active immunotherapy aims for the induction of specific antitumor immune responses; this goal requires strategies capable of increasing the immunogenicity of tumour antigens. Parvovirus B19 virus-like particles (B19-VLPs) formed of VP2 protein had been shown to be an effective multi-neoepitope delivery system capable of inducing specific cellular responses towards coupled antigens and reducing tumour growth and lung metastases in triple negative breast cancer mouse model. These findings encouraged us to further characterise these VP2 B19-VLPs by testing their capacity to simultaneously induce cellular and humoral responses towards other tumour-associated antigens, as this had not yet been evaluated. Here, we designed and evaluated in the 4T1 breast cancer model the prophylactic and therapeutic effect of VP2 B19-VLPs decorated with cellular (P53) and humoral (MUC1) epitopes. Balb/c mice were immunised with chimaeric VLPs, vehicle, or VLPs plus adjuvant. Tumour establishment and growth, lung metastasis, and cellular and humoral immune responses were evaluated. The prophylactic administration of chimaeric VLPs without adjuvant prevented the establishment of the tumour, while by therapeutic administration, chimaeric VLPs induced smaller tumour growth and decreased the number of metastases in the lung compared to wild-type VLPs. chimaeric VLPs induced high antibody titres towards the MUC1 epitope, as well as specific cellular responses towards P53 epitopes in lymph nodes local to the tumour. Our results reinforce and extend the utility of VP2 B19-VLPs as an encouraging tumour antigen delivery system in cancer immunotherapy able to improve tumour immunity in TNBC by inducing cellular and humoral immune responses.


Subject(s)
Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Parvovirus B19, Human/immunology , Triple Negative Breast Neoplasms/therapy , Vaccines, Virus-Like Particle/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Antigens, Neoplasm/administration & dosage , Bacillus thuringiensis Toxins/administration & dosage , Cancer Vaccines/administration & dosage , Cell Line, Tumor , Disease Models, Animal , Endotoxins/administration & dosage , Female , Hemolysin Proteins/administration & dosage , Humans , Immunity, Cellular , Immunity, Humoral , Immunogenicity, Vaccine , Insect Proteins , Mice , Receptors, Cell Surface , Triple Negative Breast Neoplasms/immunology , Triple Negative Breast Neoplasms/pathology , Vaccines, Virus-Like Particle/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...